Activating MET kinase domain mutations define a novel molecular subtype of non–small cell lung cancer that is clinically targetable with the MET inhibitor elzovantinib (TPX-0022).
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Federica Pecci, Biagio Ricciuti, Joao Victor Machado Alessi, Adriana Paula de Castro Barrichello, Victor R. Vaz, Giuseppe Lamberti, Jessica Kim Lee, Alexa Betzig Schrock, Vikas K Goel, Zach Zimmerman, Magda Bahcall, Pasi A. Janne, Mark M. Awad
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281757952